IRON vs IRWD
IRON: Disc Medicine is a clinical-stage biopharmaceutical firm advancing a pipeline of novel therapies to treat serious hematologic and red blood cell disorders by targeting heme biosynthesis and iron homeostasis. IRWD: Ironwood Pharmaceuticals is a GI-focused biotech company that generates stable profits from its blockbuster IBS-C therapy, LINZESS, while developing a pipeline for rare intestinal diseases.
Side-by-side fundamentals
| Metric | IRON | IRWD | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $74.61 | $4.23 | |
| Market cap as of 2026-08-03 | $2.9B | $696M | |
| P/E as of 2026-08-03 | n/a | 7.23 | |
| PEG as of 2026-08-03 | -0.26 | n/a | |
| Net margin as of 2026-08-03 | n/a | +28.3% | |
| Gross margin as of 2026-08-03 | n/a | +100.0% | |
| Operating margin as of 2026-08-03 | n/a | +55.4% | |
| ROE as of 2026-08-03 | -37.2% | +29.3% | IRWD higher |
| ROA as of 2026-08-03 | -33.7% | +26.0% | IRWD higher |
| Debt / equity as of 2026-08-03 | 0.09 | 0.56 | IRON lower |
| Revenue growth (YoY) as of 2026-08-03 | n/a | +13.8% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -10.3% | |
| Beta as of 2026-08-03 | 0.97 | 1.11 | |
| 1-year return as of 2026-07-27 close | +23.1% | +456.6% | IRWD higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.